Evidence map›Paper›PMID 22693946›Full record

ArticleACS nano2012

FRET-labeled siRNA probes for tracking assembly and disassembly of siRNA nanocomplexes.

Christopher A Alabi, Kevin T Love, Gaurav Sahay, Tina Stutzman, Whitney T Young, Robert Langer, Daniel G Anderson

Abstract readValidation Study
In one paragraph

Article in ACS nano, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy.IEEE transactions on nanobioscience · 2016
    Review
  7. Functional polyesters enable selective siRNA delivery to lung cancer over matched normal cells.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  8. Intracellular trafficking and exocytosis of a multi-component siRNA nanocomplex.Nanomedicine : nanotechnology, biology, and medicine · 2016
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Nanoparticles and their applications in cell and molecular biology.Integrative biology : quantitative biosciences from nano to macro · 2014
    Review
  16. Chiral cationic polyamines for chiral microcapsules and siRNA delivery.Bioorganic & medicinal chemistry letters · 2013
    Article
  17. Article
  18. Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery.Proceedings of the National Academy of Sciences of the United States of America · 2013
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Christopher A AlabiDavid H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, United States.
Kevin T Love
Gaurav Sahay
Tina Stutzman
Whitney T Young
Robert Langer
Daniel G Anderson
Massachusetts Institute of Technology · USHarvard–MIT Division of Health Sciences and Technology · USUniversity of Toledo · US

Funding

Controlled Release of MacromoleculesR37EB000244 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL · 2008 to 2017
$3.9M
Targeted Nanoparticle DNA Therapy for Ovarian CancerR01CA132091 · NCI · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI SAWICKI, JANET A · 2008 to 2012
$1.4M
Targeting Nanoparticle DNA Delivery to Prostate TumorsR01CA115527 · NCI · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI SAWICKI, JANET A · 2007 to 2010
$1.3M
Mechanistic probe for siRNA-polyplex delivery towards potent cancer therapeuticsF32EB012351 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ALABI, CHRISTOPHER AKINLEYE · 2010 to 2011
$99k
NCI NIH HHS R01 CA115527NCI NIH HHS R01-CA115527NCI NIH HHS R01 CA132091NCI NIH HHS R01-CA132091NIBIB NIH HHS F32 EB012351NIBIB NIH HHS R37 EB000244NIBIB NIH HHS R37-EB000244
6 · The paper itself

Abstract

The assembly, stability, and timely disassembly of short interfering RNA (siRNA) nanocomplexes have the potential to affect the efficiency of siRNA delivery and gene silencing. As such, the design of new probes that can measure these properties without significantly perturbing the nanocomplexes or their environment may facilitate the study and further development of new siRNA nanocomplexes. Herein, we study Förster resonance energy transfer (FRET)-labeled siRNA probes that can track the assembly, stability, and disassembly of siRNA nanocomplexes in different environments. The probe is composed of two identical siRNAs, each labeled with a fluorophore. Upon nanocomplex formation, the siRNA-bound fluorophores become locally aggregated within the nanocomplex and undergo FRET. A key advantage of this technique is that the delivery vehicle (DV) need not be labeled, thus enabling the characterization of a large variety of nanocarriers, some of which may be difficult or even impossible to label. We demonstrate proof-of-concept by measuring the assembly of various DVs with siRNAs and show good agreement with gel electrophoresis experiments. As a consequence of not having to label the DV, we are able to determine nanocomplex biophysical parameters such as the extracellular apparent dissociation constants (K(D)) and intracellular disassembly half-life for several in-house and proprietary commercial DVs. Furthermore, the lack of DV modification allows for a true direct comparison between DVs as well as correlation between their biophysical properties and gene silencing.

Indexed as

Base SequenceDrug Delivery SystemsFluorescence Resonance Energy TransferHeLa CellsHumansLuciferasesNanostructuresNanotechnologyRNA ProbesRNA, Small InterferingTransfectionLuciferasesRNA ProbesRNA, Small Interfering

Identifiers

PMID22693946
PMCPMC3404193
OpenAlexW2014676607

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.